Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Debt to Equity (2019 - 2021)

VYNE Therapeutics (VYNE) has disclosed Debt to Equity for 3 consecutive years, with $0.45 as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Debt to Equity fell 3.16% year-over-year to $0.45, compared with a TTM value of $0.45 through Jun 2021, down 3.16%, and an annual FY2020 reading of $0.88, down 52.48% over the prior year.
  • Debt to Equity was $0.45 for Q2 2021 at VYNE Therapeutics, up from $0.36 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.86 in Q4 2019 and bottomed at $0.36 in Q1 2021.
  • Average Debt to Equity over 3 years is $0.78, with a median of $0.67 recorded in 2020.
  • Peak annual rise in Debt to Equity hit 3.16% in 2021, while the deepest fall reached 52.52% in 2021.
  • Year by year, Debt to Equity stood at $1.86 in 2019, then plummeted by 52.48% to $0.88 in 2020, then tumbled by 49.63% to $0.45 in 2021.
  • Business Quant data shows Debt to Equity for VYNE at $0.45 in Q2 2021, $0.36 in Q1 2021, and $0.88 in Q4 2020.